There is growing evidence that EGFR inhibitors confer little benefit to patients with mCRC if the primary tumor located on the right side (caecum to transverse colon) instead of left side (splenic flexure to rectum)7,8, while VEGF inhibitors exert a similar effect on left- and right-sided tumors. The gene discussed is EGFR; the disease is neoplasm.